[Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet].
Along with the decrease in kidney function arises a secondary hyperparathyroidism, which constitutes one of the most important risk factor for mortality in patients suffering from renal insufficiency. Treating secondary hyperparathyroidism is challenging, as most of the parameters of mineral metabolism are interconnected. We review here the pathophysiology and treatment options of this entity.
Bonny
O
O
Division de néphrologie, CHUV, Département de pharmacologie et de toxicologie, Université de Lausanne, 1011 Lausanne.
Burnier
M
M
D002117:Calcitriol / Q000627:therapeutic use; D002614:Chelating Agents / Q000627:therapeutic use; D000069449:Cinacalcet; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology*; D009281:Naphthalenes / Q000627:therapeutic use; D011073:Polyamines / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000150:complications*; D000069603:Sevelamer; D014808:Vitamin D Deficiency / Q000188:drug therapy; D014815:Vitamins / Q000627:therapeutic use
D002614:Chelating Agents; D009281:Naphthalenes; D011073:Polyamines; D014815:Vitamins; D000069603:Sevelamer; D002117:Calcitriol; D000069449:Cinacalcet